116 related articles for article (PubMed ID: 26272673)
1. Identification of CD8 T cell epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR(-/-) mice.
de la Poza F; Marín-López A; Castillo-Olivares J; Calvo-Pinilla E; Ortego J
Virus Res; 2015 Dec; 210():149-53. PubMed ID: 26272673
[TBL] [Abstract][Full Text] [Related]
2. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
[TBL] [Abstract][Full Text] [Related]
3. CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR
Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Brun A; Anguita J; Ortego J
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875250
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
[TBL] [Abstract][Full Text] [Related]
5. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.
de la Poza F; Calvo-Pinilla E; López-Gil E; Marín-López A; Mateos F; Castillo-Olivares J; Lorenzo G; Ortego J
PLoS One; 2013; 8(7):e70197. PubMed ID: 23894615
[TBL] [Abstract][Full Text] [Related]
6. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968
[TBL] [Abstract][Full Text] [Related]
7. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
Aksular M; Calvo-Pinilla E; Marín-López A; Ortego J; Chambers AC; King LA; Castillo-Olivares J
Vaccine; 2018 Nov; 36(46):7003-7010. PubMed ID: 30309744
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
Virus Res; 2014 Feb; 180():23-30. PubMed ID: 24333835
[TBL] [Abstract][Full Text] [Related]
9. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.
Alberca B; Bachanek-Bankowska K; Cabana M; Calvo-Pinilla E; Viaplana E; Frost L; Gubbins S; Urniza A; Mertens P; Castillo-Olivares J
Vaccine; 2014 Jun; 32(29):3670-4. PubMed ID: 24837765
[TBL] [Abstract][Full Text] [Related]
11. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
[TBL] [Abstract][Full Text] [Related]
12. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
[TBL] [Abstract][Full Text] [Related]
13. T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification.
Pinto PBA; Assis ML; Vallochi AL; Pacheco AR; Lima LM; Quaresma KRL; Pereira BAS; Costa SM; Alves AMB
Front Immunol; 2019; 10():1522. PubMed ID: 31333657
[TBL] [Abstract][Full Text] [Related]
14. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
[TBL] [Abstract][Full Text] [Related]
15. Identification and immunogenicity of two new HLA-A*0201-restricted CD8+ T-cell epitopes on dengue NS1 protein.
Tian J; Zeng G; Pang X; Liang M; Zhou J; Fang D; Liu Y; Li D; Jiang L
Int Immunol; 2012 Apr; 24(4):207-18. PubMed ID: 22298881
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes.
Gao G; Wang Q; Dai Z; Calcedo R; Sun X; Li G; Wilson JM
Hum Gene Ther; 2008 Sep; 19(9):927-36. PubMed ID: 18788905
[TBL] [Abstract][Full Text] [Related]
17. Ovine and murine T cell epitopes from the non-structural protein 1 (NS1) of bluetongue virus serotype 8 (BTV-8) are shared among viral serotypes.
Rojas JM; Peña L; Martín V; Sevilla N
Vet Res; 2014 Mar; 45(1):30. PubMed ID: 24621015
[TBL] [Abstract][Full Text] [Related]
18. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.
Castillo-Olivares J; Calvo-Pinilla E; Casanova I; Bachanek-Bankowska K; Chiam R; Maan S; Nieto JM; Ortego J; Mertens PP
PLoS One; 2011 Jan; 6(1):e16503. PubMed ID: 21298069
[TBL] [Abstract][Full Text] [Related]
19. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.
El Garch H; Crafford JE; Amouyal P; Durand PY; Edlund Toulemonde C; Lemaitre L; Cozette V; Guthrie A; Minke JM
Vet Immunol Immunopathol; 2012 Sep; 149(1-2):76-85. PubMed ID: 22763149
[TBL] [Abstract][Full Text] [Related]
20. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.
Lulla V; Lulla A; Wernike K; Aebischer A; Beer M; Roy P
J Virol; 2016 Aug; 90(16):7405-7414. PubMed ID: 27279609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
